Literature DB >> 22740897

Variation in myxoid liposarcoma: Clinicopathological examination of four cases with detectable TLS-CHOP or EWS-CHOP fusion transcripts whose histopathological diagnosis was other than myxoid liposarcoma.

Kayo Suzuki1, Yoshito Matsui, Nobuyuki Hashimoto, Norifumi Naka, Nobuhito Araki, Tomoatsu Kimura, Hideki Yoshikawa, Takafumi Ueda.   

Abstract

Liposarcomas are separated into clinicopathological entities by a characteristic morphological spectrum and distinctive genetic changes. Myxoid liposarcoma (MLS) represents one such entity with specific chromosomal translocations leading to the generation of fusion genes, the human translocation liposarcoma (TLS)-CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) or the Ewing sarcoma (EWS)-CHOP. In the present study, four cases of liposarcoma with detection of TLS-CHOP or EWS-CHOP, whose postoperative diagnosis was other than MLS (one well-differentiated liposarcoma, two de-differentiated liposarcomas and one unclassified) were examined for medical records, imaging data and histopathology. Clinical records demonstrated that three of the four cases were considerably difficult to diagnose definitively, and histopathological re-examination pointed out areas of myxomatous change as a minor component (<10%). Their dominant components (>90%) resembled pleomorphic sarcoma, pleomorphic malignant fibrous histiocytoma and monophasic synovial sarcoma. The current cases may represent an extreme variant of the morphological spectrum within MLS. In cases of difficulty in making definitive diagnosis of soft tissue sarcoma by standard histopathological examination and identification of myxoid stroma even as a minor component, analyzing TLS-CHOP and EWS-CHOP fusion genes may aid the diagnosis of unusual MLS.

Entities:  

Year:  2011        PMID: 22740897      PMCID: PMC3362345          DOI: 10.3892/ol.2011.480

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  12 in total

1.  A novel FUS/CHOP chimera in myxoid liposarcoma.

Authors:  I Panagopoulos; F Mertens; M Isaksson; N Mandahl
Journal:  Biochem Biophys Res Commun       Date:  2000-12-29       Impact factor: 3.575

2.  A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma.

Authors:  Taisuke Hosaka; Yasuaki Nakashima; Katsuyuki Kusuzaki; Hiroaki Murata; Tomitaka Nakayama; Takeharu Nakamata; Tomoki Aoyama; Takeshi Okamoto; Kohichi Nishijo; Nobuhito Araki; Tadao Tsuboyama; Takashi Nakamura; Junya Toguchida
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

3.  Specificity of fusion genes in adipocytic tumors.

Authors:  Takahiro Kubo; Yoshito Matsui; Norifumi Naka; Nobuhito Araki; Akira Myoui; Kenji Endo; Natsuo Yasui; Osamu Ohtani; Kayo Suzuki; Tomoatsu Kimura; Hideki Yoshikawa; Takafumi Ueda
Journal:  Anticancer Res       Date:  2010-02       Impact factor: 2.480

4.  Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion.

Authors:  B Bode-Lesniewska; S Frigerio; U Exner; M T Abdou; H Moch; D R Zimmermann
Journal:  Genes Chromosomes Cancer       Date:  2007-11       Impact factor: 5.006

5.  Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.

Authors:  C R Antonescu; S J Tschernyavsky; R Decuseara; D H Leung; J M Woodruff; M F Brennan; J A Bridge; J R Neff; J R Goldblum; M Ladanyi
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

6.  A novel type of EWS-CHOP fusion gene in myxoid liposarcoma.

Authors:  Yoshito Matsui; Takafumi Ueda; Takahiro Kubo; Tadashi Hasegawa; Yasuhiko Tomita; Mina Okamoto; Akira Myoui; Shigeki Kakunaga; Natsuo Yasui; Hideki Yoshikawa
Journal:  Biochem Biophys Res Commun       Date:  2006-07-28       Impact factor: 3.575

7.  Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas.

Authors:  C R Antonescu; A Elahi; M Humphrey; M Y Lui; J H Healey; M F Brennan; J M Woodruff; S C Jhanwar; M Ladanyi
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

8.  Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.

Authors:  Marc Ladanyi; Cristina R Antonescu; Denis H Leung; James M Woodruff; Akira Kawai; John H Healey; Murray F Brennan; Julia A Bridge; James R Neff; Frederic G Barr; Jeffrey D Goldsmith; John S J Brooks; John R Goldblum; Syed Z Ali; Janet Shipley; Colin S Cooper; Cyril Fisher; Björn Skytting; Olle Larsson
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

9.  Myxoid liposarcoma with EWS-CHOP type 1 fusion gene.

Authors:  Kayo Suzuki; Yoshito Matsui; Kenji Endo; Takahiro Kubo; Tadashi Hasegawa; Tomoatsu Kimura; Osamu Ohtani; Natsuo Yasui
Journal:  Anticancer Res       Date:  2010-11       Impact factor: 2.480

10.  TLS-CHOP target gene DOL54 expression in liposarcomas and malignant fibrous histiocytomas.

Authors:  Hideharu Domoto; Taisuke Hosaka; Kosuke Oikawa; Tetsuya Ohbayashi; Tsuyoshi Ishida; Miki Izumi; Keiichi Iwaya; Junya Toguchida; Masahiko Kuroda; Kiyoshi Mukai
Journal:  Pathol Int       Date:  2002-08       Impact factor: 2.534

View more
  3 in total

Review 1.  Molecular strategies for detecting chromosomal translocations in soft tissue tumors (review).

Authors:  Margherita Cerrone; Monica Cantile; Francesca Collina; Laura Marra; Giuseppina Liguori; Renato Franco; Annarosaria De Chiara; Gerardo Botti
Journal:  Int J Mol Med       Date:  2014-04-04       Impact factor: 4.101

2.  Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.

Authors:  Kayo Suzuki; Yoshito Matsui; Mami Higashimoto; Yoshiharu Kawaguchi; Shoji Seki; Hiraku Motomura; Takeshi Hori; Yasuhito Yahara; Masahiko Kanamori; Tomoatsu Kimura
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

3.  The oncogenic transcription factor FUS-CHOP can undergo nuclear liquid-liquid phase separation.

Authors:  Izzy Owen; Debra Yee; Hala Wyne; Theodora Myrto Perdikari; Victoria Johnson; Jeremy Smyth; Robert Kortum; Nicolas L Fawzi; Frank Shewmaker
Journal:  J Cell Sci       Date:  2021-09-03       Impact factor: 5.235

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.